Pear Ther­a­peu­tics nabs $80M Se­ries D to com­mer­cial­ize three dig­i­tal ther­a­peu­tics

As the pan­dem­ic rages on, vir­tu­al care op­tions have in­vestors champ­ing at the bit. Boston-based Pear Ther­a­peu­tics is the lat­est to ben­e­fit, reel­ing in $80 mil­lion to com­mer­cial­ize its three pre­scrip­tion dig­i­tal ther­a­peu­tics.

The dig­i­tal ther­a­peu­tics um­brel­la en­com­pass­es tech­nol­o­gy like mo­bile apps and telemed­i­cine plat­forms de­signed to pre­vent, treat or man­age dis­ease. Some are used alone, while oth­ers are com­bined with med­ica­tion.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN